Literature DB >> 25198910

Reinvestigating nanoprecipitation via Box-Behnken design: a systematic approach.

Yuvraj Singh1, Preeti Ojha, Mukesh Srivastava, Manish K Chourasia.   

Abstract

This work demonstrates Box-Behnken design (BBD)'s capability in exploring scientific principles governing a process, different from its use in process optimisation. We have investigated nanoprecipitation (NP) of temozolomide with polycaprolactone. Five factors, surfactant, stirring speed (SS), dropping rate (DR), phase-volume ratio (PVR) and drug-polymer ratio (DPR) were varied over three levels. Corresponding particle size (238.9 ± 42.24 nm), zeta potential (ZP, -5.92 ± 3.15 mV), poly dispersity index (PDI, 0.176 ± 0.06) and entrapment efficiency (EE, 65.74 ± 9.83%) were put into different polynomial equations. Analysis of variance, lack of fit tests and regression analysis was applied on these equations to determine the one with best fit. This selected equation was subsequently adapted as the model to describe influence of factors on NP. 3D response surface plots corresponding to models and diagnostic plots relatable to normality of residuals were also constructed. In conclusion, application of BBD efficiently strategised experimental foray conducted to elucidate NP.

Entities:  

Keywords:  Box–Behnken design; design of experiment; nanoprecipitation; polycaprolactone; polymeric nanoparticles; temozolomide

Mesh:

Substances:

Year:  2014        PMID: 25198910     DOI: 10.3109/02652048.2014.950710

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  1 in total

1.  Doxorubicin Hydrochloride Loaded Zymosan-Polyethylenimine Biopolymeric Nanoparticles for Dual 'Chemoimmunotherapeutic' Intervention in Breast Cancer.

Authors:  Vivek K Pawar; Yuvraj Singh; Komal Sharma; Arpita Shrivastav; Abhisheak Sharma; Akhilesh Singh; Jaya Gopal Meher; Pankaj Singh; Kavit Raval; Himangshu K Bora; Dipak Datta; Jawahar Lal; Manish K Chourasia
Journal:  Pharm Res       Date:  2017-06-12       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.